Collegium Pharmaceutical (Cumberland, RI) commercial-stage specialty pharmaceutical company focused on late-stage development therapeutics for central nervous system, respiratory and skin related disorders, closed a $20M Series D financing. Participants include Frazier Healthcare Ventures.